繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed (Grey Market Trading Session: 16:15-18:30)
Name▼
/
Code▲
 Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
Anjoy Foods
02648.HK
Grey Market Today
 Packaged Foods 60.000 100 6,667
-
-
 Detail Quote
Last update: 2025-07-02 12:30:06
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
FWD
01828.HK		 Life & Health Insurance 38 100 N/A 2025/07/02 2025/07/04 2025/07/07
Fortior
01304.HK		 Semiconductors & Semiconductor Equipment N/A 100 12,172 2025/07/04 2025/07/08 2025/07/09
Shougang Lanza
02553.HK		 Diversified Chemicals 14.5-18.88 200 3,814 2025/07/04 2025/07/08 2025/07/09
Geekplus-W
02590.HK		 Advanced hardware and software 16.8 200 N/A 2025/07/04 2025/07/08 2025/07/09
Xunzhong
02597.HK		 Telecommunication Services 13.55-15.15 500 7,651 2025/07/04 2025/07/08 2025/07/09
Dazhong Dental
02651.HK		 Health Care Services 20-21.4 100 2,162 2025/07/04 2025/07/08 2025/07/09
Lens
06613.HK		 Next-generation information technology 17.38-18.18 200 3,673 2025/07/04 2025/07/08 2025/07/09
Sunshine Pharma
06887.HK		 Pharmaceuticals N/A 100 N/A N/A Not applicable 2025/08/07
MEGA GENOMICS (06667.HK)
Summary
We are a leading genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. As of December 31, 2021, we performed over 12 million genetic tests since our establishment in 2016, with an average of over 246,000 tests performed per month in 2020. According to Frost & Sullivan, we are the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered. Also according to Frost & Sullivan, we were the largest genetic testing platform for cancer screening in China as measured by the number of tests administered in 2020.

Our significant consumer base in China and automated facility enable us to proactively and efficiently meet the significant demands for genetic testing services in China. According to Frost & Sullivan, the market for genetic testing in China was RMB15.1 billion in 2020 and is expected to reach RMB48.7 billion in 2025 at a CAGR of 26.4% from 2020 to 2025, and is expected to further grow to RMB153.6 billion in 2030 at a CAGR of 25.8% from 2025 to 2030. The consumer genetic testing market is a subset of the genetic testing market in China and accounted for 3.1% of such market by revenue in 2020, according to Frost & Sullivan. Furthermore, the penetration rate of consumer genetic testing in 2020 was only 0.8% in China and 8.8% in the United States, which is calculated by dividing the accumulative number of consumer genetic testing users by the population of the country. Compared to the United States, China’s significantly larger population and substantially lower penetration rate represent significant potential for market growth. The number of Chinese consumers who underwent genetic testing grew at a CAGR of 69.4% from 2016 to 2020 and is expected to exceed 167.2 million by 2030. In addition, the overall penetration rate of cancer screening in China is relatively low compared to more developed countries. In China, routine colorectal cancer screening is recommended for people between 40 and 74 years old, particularly those who live in urban areas, and this population reached 632.5 million in 2019; in the United States, routine colorectal cancer screening is recommended for people between 50 and 75 years old, and this population reached 93.0 million in 2019. In 2019, the penetration rate of colorectal cancer screening was 16.4% among the population recommended for colorectal cancer screening in China, which was significantly lower than 60.1% in the United States. Gastric cancer is a more common cancer type among the East Asian population. In China, routine gastric cancer screening is recommended for people who are 40 and older, and this population reached 690.1 million in 2019. In Japan, a country whose citizens share a number of demographic traits and dietary habits with people in China, routine gastric cancer screening is recommended for people who are 50 and older, and this population reached 59.7 million in 2019. Gastric cancer had a penetration rate of 21.6% among the population recommended for gastric cancer screening in China in 2019, while Japan had a penetration rate of 43.0% in 2019. China’s rapid improvement in health awareness, payment ability and medical insurance coverage are all factors for potential growth for an already significant market. The combined market size reached approximately RMB8.8 billion in 2020 for the top five cancer screening markets in China, including gastric cancer, colorectal cancer, lung cancer, breast cancer and liver cancer, according to Frost & Sullivan.

In 2020, our market share in China’s consumer genetic testing market, as measured by the number of tests administered, exceeded 60%, which was more than ten times the number of tests administered by our closest competitor, according to Frost & Sullivan. Our market share was 34.2% in terms of revenue generated in 2020, which ranked first in China’s consumer genetic testing market and was higher than the combined market shares of our five closest competitors. In the Track Record Period, we were the only company that achieved profitability in the consumer genetic testing industry in China according to Frost & Sullivan. In the cancer screening market, we were the only company whose cumulative number of tests administered exceeded 453,000 tests as of December 31, 2021, which were significantly above the industry average according to Frost & Sullivan. In addition, our ability to provide comprehensive services by leveraging our industry-leading technology platforms and to achieve economies of scale with large sample size enables us to improve our profitability level. According to Frost & Sullivan, our gross profit margin of cancer screening services recorded 80.5% in 2020, which was significantly higher than the industry average of 60.3% in the same field in China in 2020.

We are a genetic testing company in China with integrated capabilities that cover the full cycle of upstream, midstream and downstream segments. We adopt a platform-based business model that focuses on both product development and commercialization of our services and products. As a result, we generate synergies from our combination of development with commercialization that help to grow our business. This combination enables us to become a clear market leader with high growth, sustainable profitability and a scalable business model with significant entry barriers. The diagram below illustrates our platform-based operations.

The upstream segment of our business involves technologies developed by our in-house research and development team and cooperation with our third-party partners. Our research and development efforts currently focus on the development of LDT services and IVD products. A LDT is typically not a standalone product or device, but a self-developed procedure that uses testing kits developed in-house that are not registered with the NMPA. IVD products refer to reagents or testing kits that are registered with the NMPA and are regulated as medical devices. As of December 31, 2021, we had 91 multi-dimensional commercialized testing solutions for consumer genetic testing and cancer screening that cover a wide range of prices. Out of our 91 testing solutions, 80 of them were comprised of our self-developed LDT services and 11 of them were provided with IVD testing kits procured from Independent Third Parties. In addition to our existing service portfolio, we have been developing eight IVD product candidates in our pipeline. As of the Latest Practicable Date, we have yet to obtain NMPA registration for any of our IVD product candidates. We also introduce new testing solutions from time to time to meet emerging consumer demands. For example, we developed nucleic acid testing capability and offered COVID-19-related testing services in May 2020 in response to the outbreak of the COVID-19 pandemic.



Source: Mega Genomics (06667) Prospectus (IPO Date : 2022/06/10)
Listing Market MAIN
Industry Biotechnology - Supplies & Services
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Meinian OneHealth Healthcare Holdings Co., Ltd. (16.61%)
Kastle Limited (12.16%)
Guo Meiling (11.96%)
Yu Rong & Associates (8.38%)
Niu Zhencai & Associates (5.39%)
Directors Yu Rong (Honorary Chairman and Executive Director)
Guo Meiling (Honorary Chairman and Non-Executive Director)
Lin Lin (Chairman and Executive Director)
Jiang Jing (Chief Executive Officer and Chief Financial Officer and Executive Director)
Jia Qingfeng (Independent Non-Executive Director)
Xie Dan (Independent Non-Executive Director)
Zhang Ying (Independent Non-Executive Director)
Company Secretary Ng Ka Chi
Principal Bankers Bank of Communications Co., Ltd.
Standard Chartered Bank
Solicitors DeHeng Law Offices
Auditors Ernst & Young
Registered Office Suite 1704, 17/F, Alexandra House, 18 Chater Road, Central, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address https://www.megagenomics.cn/
Email Address ir@megagenomics.cn
Tel No (86 400) 008-0280
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.